GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spectrum Pharmaceuticals Inc (NAS:SPPI) » Definitions » Beneish M-Score

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Beneish M-Score : 0.00 (As of May. 05, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Spectrum Pharmaceuticals Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Spectrum Pharmaceuticals's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Spectrum Pharmaceuticals was 0.00. The lowest was -3.58. And the median was -2.94.


Spectrum Pharmaceuticals Beneish M-Score Historical Data

The historical data trend for Spectrum Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spectrum Pharmaceuticals Beneish M-Score Chart

Spectrum Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Spectrum Pharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Spectrum Pharmaceuticals's Beneish M-Score

For the Biotechnology subindustry, Spectrum Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spectrum Pharmaceuticals's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spectrum Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Spectrum Pharmaceuticals's Beneish M-Score falls into.



Spectrum Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Spectrum Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * +0.528 * +0.404 * +0.892 * +0.115 *
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * +4.679 * -0.327 *
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar23) TTM:Last Year (Mar22) TTM:
Total Receivables was $33.64 Mil.
Revenue was 15.615 + 10.114 + 0 + 0 = $25.73 Mil.
Gross Profit was 14.552 + 8.322 + 0 + 0 = $22.87 Mil.
Total Current Assets was $105.38 Mil.
Total Assets was $107.68 Mil.
Property, Plant and Equipment(Net PPE) was $2.05 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.22 Mil.
Selling, General, & Admin. Expense(SGA) was $42.94 Mil.
Total Current Liabilities was $38.88 Mil.
Long-Term Debt & Capital Lease Obligation was $28.84 Mil.
Net Income was -5.007 + -8.986 + -21.925 + -29.048 = $-64.97 Mil.
Non Operating Income was 0.248 + 0.203 + -0.443 + -3.757 = $-3.75 Mil.
Cash Flow from Operations was -21.44 + -25.338 + -17.909 + -23.446 = $-88.13 Mil.
Total Receivables was $0.64 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $93.18 Mil.
Total Assets was $100.05 Mil.
Property, Plant and Equipment(Net PPE) was $2.53 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.29 Mil.
Selling, General, & Admin. Expense(SGA) was $55.96 Mil.
Total Current Liabilities was $39.21 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(33.638 / 25.729) / (0.639 / 0)
=1.307396 /
=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0 / 0) / (22.874 / 25.729)
= / 0.889036
=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (105.378 + 2.052) / 107.675) / (1 - (93.181 + 2.525) / 100.054)
=0.002275 / 0.043457
=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=25.729 / 0
=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.294 / (0.294 + 2.525)) / (0.22 / (0.22 + 2.052))
=0.104292 / 0.096831
=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(42.944 / 25.729) / (55.961 / 0)
=1.669089 /
=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((28.84 + 38.881) / 107.675) / ((0 + 39.208) / 100.054)
=0.628939 / 0.391868
=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-64.966 - -3.749 - -88.133) / 107.675
=0.249974

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.


Spectrum Pharmaceuticals Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Spectrum Pharmaceuticals's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
Pilot House - Lewis Wharf, 2 Atlantic Avenue, 6th Floor, Boston, MA, USA, 02110
Spectrum Pharmaceuticals Inc operates in the healthcare sector in the United States. It is a biopharmaceutical company with a primary strategy comprised of acquiring, developing and commercializing novel and targeted oncology therapies. Eflapegrastim and Poziotinib are it's current drugs in last stage development. Eflapegrastim is a novel long-acting granulocyte colony-stimulating factor ("G-CSF") for the treatment of chemotherapy-induced neutropenia and Poziotinib is a novel irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer ("NSCLC") tumors with various mutations. It has one segment that is focused exclusively on developing and marketing oncology and hematology drug products.
Executives
Juhyun Lim director 11500 S. EASTERN AVE., SUITE 220, HENDERSON NV 89052
Fischer Seth H.z. director C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Brittany Bradrick director C/O DERMATA THERAPEUTICS, INC., 3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO CA 92130
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Nora Brennan officer: See Remarks C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Keith M Mcgahan officer: Chief Legal Officer 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Thomas J Riga director, officer: CEO & President 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
Francois Lebel officer: Chief Medical Officer 4100 LEXINGTO AVE N, ARDEN HILLS MN 55126-2998
Dolatrai Vyas director 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Kurt A Gustafson officer: EVP & Chief Financial Officer 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Joseph W. Turgeon officer: Chief Commercial Officer 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Elizabeth Czerepak director 201 ROUTE 17 NORTH, RUTHERFORD NJ 07070
Maida Anthony E Iii director 157 TECHNOLOGY DR, IRVINE CA 92618
Stuart Mitchell Krassner director 157 TEHCNOLOGY DRIVE, IRVINE CA 92618

Spectrum Pharmaceuticals (Spectrum Pharmaceuticals) Headlines

From GuruFocus

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SPPI, HOTH

By sperokesalga sperokesalga 04-28-2023